Literature DB >> 20100281

Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans.

Y Falkén1, P M Hellström, G J Sanger, O Dewit, G Dukes, P Grybäck, J J Holst, E Näslund.   

Abstract

BACKGROUND: Ghrelin is produced by enteroendocrine cells in the gastric mucosa and stimulates gastric emptying in healthy volunteers and patients with gastroparesis in short-term studies. The aim of this study was to evaluate effects of intravenous ghrelin on gastrointestinal motility and glucose homeostasis during a 6-h infusion in humans.
METHODS: Ghrelin (15 pmol kg(-1) min(-1)) or saline was infused intravenously for 360 min after intake of radio-opaque markers, acetaminophen, and lactulose after a standardized breakfast in 12 male volunteers. Gastric emptying, orocecal transit, colonic transit, postprandial plasma concentrations of glucose, insulin, glucagon-like peptide-1 (GLP-1), and peptide YY were assessed. In vitro studies of gastrointestinal muscle contractility were performed. KEY
RESULTS: The gastric emptying rate was faster for ghrelin compared to saline (P = 0.002) with a shorter half-emptying time (50.3 +/- 3.9 vs 59.9 +/- 4.4 min, P = 0.004). There was no effect of ghrelin on orocecal or colonic transit. Postprandial elevations of plasma glucose, insulin, and GLP-1 occurred 15 min earlier and were higher with ghrelin. The insulinogenic index did not change during ghrelin infusion. Basal in vitro contractility was unaffected by ghrelin. CONCLUSIONS & INFERENCES: The effect of a 6-h ghrelin infusion on gastrointestinal motility is limited to the stomach without affecting orocecal or colonic transit. Plasma glucose, insulin, and GLP-1 are elevated postprandially, probably as a result of the hastened gastric emptying. Changes in glucose homeostasis as a consequence of stimulated gastric emptying and hormone release, need to be taken into account in the use of pharmacological stimulants for the treatment of motility disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100281     DOI: 10.1111/j.1365-2982.2009.01463.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  12 in total

1.  Diet-induced adaptation of vagal afferent function.

Authors:  Stephen Kentish; Hui Li; Lisa K Philp; Tracey A O'Donnell; Nicole J Isaacs; Richard L Young; Gary A Wittert; L Ashley Blackshaw; Amanda J Page
Journal:  J Physiol       Date:  2011-11-07       Impact factor: 5.182

2.  Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.

Authors:  Jenny Tong; Harold W Davis; Amalia Gastaldelli; David D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2016-04-07       Impact factor: 5.958

Review 3.  Peripheral neural targets in obesity.

Authors:  Amanda J Page; Erin Symonds; Madusha Peiris; L Ashley Blackshaw; Richard L Young
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  A Higher Preoperative Glycemic Profile Is Associated with Rapid Gastric Emptying After Sleeve Gastrectomy for Obese Subjects.

Authors:  Po-Jen Yang; Mei-Fang Cheng; Wei-Shiung Yang; Ming-Shian Tsai; Po-Chu Lee; Chiung-Nien Chen; Ming-Tsan Lin; Ping-Huei Tseng
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

Review 5.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

Review 6.  Hormonal signaling in the gut.

Authors:  Clémence D Côté; Melika Zadeh-Tahmasebi; Brittany A Rasmussen; Frank A Duca; Tony K T Lam
Journal:  J Biol Chem       Date:  2014-02-27       Impact factor: 5.157

Review 7.  Diabetic gastroparesis: functional/morphologic background, diagnosis, and treatment options.

Authors:  Viktor J Horváth; Ferenc Izbéki; Csaba Lengyel; Péter Kempler; Tamás Várkonyi
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

8.  Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food.

Authors:  Anthony P Goldstone; Christina G Prechtl; Samantha Scholtz; Alexander D Miras; Navpreet Chhina; Giuliana Durighel; Seyedeh S Deliran; Christian Beckmann; Mohammad A Ghatei; Damien R Ashby; Adam D Waldman; Bruce D Gaylinn; Michael O Thorner; Gary S Frost; Stephen R Bloom; Jimmy D Bell
Journal:  Am J Clin Nutr       Date:  2014-04-23       Impact factor: 7.045

9.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

Review 10.  Ghrelin.

Authors:  T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp
Journal:  Mol Metab       Date:  2015-03-21       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.